Negotiations have not been suspended after Mabion, a Polish listed company, announced cooperation with a foreign drug concern. On the contrary, the head of ABM declares that binding decisions can be expected very quickly. Currently, the talks are focused on the purchase of a license for the production of an covid vaccine.
“The decision to choose a partner should be made within a few weeks at the most,” tells us Radosław Sierpiński, head of the Medical Research Agency.
In search of a place for the production line, an audit of Polish factories is underway.
Main competitors are: AstraZeneca, Sanofi and CureVac.